Literature DB >> 27783918

A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.

Richard K Albert, David H Au, Amanda L Blackford, Richard Casaburi, J Allen Cooper, Gerard J Criner, Philip Diaz, Anne L Fuhlbrigge, Steven E Gay, Richard E Kanner, Neil MacIntyre, Fernando J Martinez, Ralph J Panos, Steven Piantadosi, Frank Sciurba, David Shade, Thomas Stibolt, James K Stoller, Robert Wise, Roger D Yusen, James Tonascia, Alice L Sternberg, William Bailey.   

Abstract

BACKGROUND: Long-term treatment with supplemental oxygen has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation.
METHODS: We originally designed the trial to test whether long-term treatment with supplemental oxygen would result in a longer time to death than no use of supplemental oxygen among patients who had stable COPD with moderate resting desaturation (oxyhemoglobin saturation as measured by pulse oximetry [Spo2], 89 to 93%). After 7 months and the randomization of 34 patients, the trial was redesigned to also include patients who had stable COPD with moderate exercise-induced desaturation (during the 6-minute walk test, Spo2 ≥80% for ≥5 minutes and <90% for ≥10 seconds) and to incorporate the time to the first hospitalization for any cause into the new composite primary outcome. Patients were randomly assigned, in a 1:1 ratio, to receive long-term supplemental oxygen (supplemental-oxygen group) or no long-term supplemental oxygen (no-supplemental-oxygen group). In the supplemental-oxygen group, patients with resting desaturation were prescribed 24-hour oxygen, and those with desaturation only during exercise were prescribed oxygen during exercise and sleep. The trial-group assignment was not masked.
RESULTS: A total of 738 patients at 42 centers were followed for 1 to 6 years. In a time-to-event analysis, we found no significant difference between the supplemental-oxygen group and the no-supplemental-oxygen group in the time to death or first hospitalization (hazard ratio, 0.94; 95% confidence interval [CI], 0.79 to 1.12; P=0.52), nor in the rates of all hospitalizations (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio, 1.08; 95% CI, 0.98 to 1.19), and COPD-related hospitalizations (rate ratio, 0.99; 95% CI, 0.83 to 1.17). We found no consistent between-group differences in measures of quality of life, lung function, and the distance walked in 6 minutes.
CONCLUSIONS: In patients with stable COPD and resting or exercise-induced moderate desaturation, the prescription of long-term supplemental oxygen did not result in a longer time to death or first hospitalization than no long-term supplemental oxygen, nor did it provide sustained benefit with regard to any of the other measured outcomes. (Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services; LOTT ClinicalTrials.gov number, NCT00692198 .).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27783918      PMCID: PMC5216457          DOI: 10.1056/NEJMoa1604344

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

1.  Reliability and validity of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale in older men.

Authors:  Adam P Spira; Sherry A Beaudreau; Katie L Stone; Eric J Kezirian; Li-Yung Lui; Susan Redline; Sonia Ancoli-Israel; Kristine Ensrud; Anita Stewart
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-09-20       Impact factor: 6.053

2.  A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients.

Authors:  A Chaouat; E Weitzenblum; R Kessler; C Charpentier; M Enrhart; R Schott; P Levi-Valensi; J Zielinski; L Delaunois; R Cornudella; J Moutinho dos Santos
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

3.  Exercise hemodynamics and gas exchange in patients with chronic obstruction pulmonary disease, sleep desaturation, and a daytime PaO2 above 60 mm Hg.

Authors:  E C Fletcher; R A Luckett; T Miller; J G Fletcher
Journal:  Am Rev Respir Dis       Date:  1989-11

4.  St. George's Respiratory Questionnaire: MCID.

Authors:  Paul W Jones
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

5.  The long-term effect of ambulatory oxygen in normoxaemic COPD patients: a randomised study.

Authors:  Thomas Ringbaek; Gerd Martinez; Peter Lange
Journal:  Chron Respir Dis       Date:  2013-02-21       Impact factor: 2.444

Review 6.  Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial.

Authors:  James K Stoller; Ralph J Panos; Samuel Krachman; Dennis E Doherty; Barry Make
Journal:  Chest       Date:  2010-07       Impact factor: 9.410

7.  Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease.

Authors:  R M Kaplan; C J Atkins; R Timms
Journal:  J Chronic Dis       Date:  1984

8.  Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients.

Authors:  Margareta Emtner; Janos Porszasz; Mary Burns; Attila Somfay; Richard Casaburi
Journal:  Am J Respir Crit Care Med       Date:  2003-07-17       Impact factor: 21.405

9.  Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mm Hg.

Authors:  E C Fletcher; J Miller; G W Divine; J G Fletcher; T Miller
Journal:  Chest       Date:  1987-10       Impact factor: 9.410

10.  Validity of reporting oxygen uptake efficiency slope from submaximal exercise using respiratory exchange ratio as secondary criterion.

Authors:  Wilby Williamson; Jonathan Fuld; Kate Westgate; Karl Sylvester; Ulf Ekelund; Soren Brage
Journal:  Pulm Med       Date:  2012-05-14
View more
  68 in total

1.  Characteristics at the time of oxygen initiation associated with its adherence: Findings from the COPD Long-term Oxygen Treatment Trial.

Authors:  Marilyn L Moy; Kathleen F Harrington; Alice L Sternberg; Jerry A Krishnan; Richard K Albert; David H Au; Richard Casaburi; Gerard J Criner; Philip Diaz; Richard E Kanner; Ralph J Panos; Thomas Stibolt; James K Stoller; James Tonascia; Roger D Yusen; Ai-Yui M Tan; Anne L Fuhlbrigge
Journal:  Respir Med       Date:  2019-02-13       Impact factor: 3.415

2.  The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned.

Authors:  Roger D Yusen; Gerard J Criner; Alice L Sternberg; David H Au; Anne L Fuhlbrigge; Richard K Albert; Richard Casaburi; James K Stoller; Kathleen F Harrington; J Allen D Cooper; Philip Diaz; Steven Gay; Richard Kanner; Neil MacIntyre; Fernando J Martinez; Steven Piantadosi; Frank Sciurba; David Shade; Thomas Stibolt; James Tonascia; Robert Wise; William C Bailey
Journal:  Ann Am Thorac Soc       Date:  2018-01

3.  Poor Outcomes Among Patients With Chronic Obstructive Pulmonary Disease With Higher Risk for Undiagnosed Obstructive Sleep Apnea in the LOTT Cohort.

Authors:  Lucas M Donovan; Laura C Feemster; Edmunds M Udris; Matthew F Griffith; Laura J Spece; Brian N Palen; Ken He; Sairam Parthasarathy; Kingman P Strohl; Vishesh K Kapur; David H Au
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

4.  Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation.

Authors:  Byron Thomashow; James D Crapo; M Bradley Drummond; MeiLan K Han; Ravi Kalhan; Elisha Malanga; Vinny Malanga; David M Mannino; Stephen Rennard; Frank C Sciurba; Kristen S Willard; Robert Wise; Barbara Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2019-07-24

5.  Long term oxygen therapy-it is still relevant?

Authors:  Surinder K Jindal
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

6.  Who Needs Oxygen with Positive Airway Pressure Therapy?

Authors:  Susmita Chowdhuri; Abdulghani Sankari; James A Rowley
Journal:  J Clin Sleep Med       Date:  2017-01-15       Impact factor: 4.062

7.  Long-term oxygen for COPD with moderate desaturation.

Authors:  Ludovico Furlan; Luca Erba
Journal:  Intern Emerg Med       Date:  2017-02-10       Impact factor: 3.397

8.  OSA/COPD Overlap: Convergence on a Theme?

Authors:  Jennifer J Dorsch; Emerson M Wickwire
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

Review 9.  Pharmacogenomics of chronic obstructive pulmonary disease.

Authors:  Craig P Hersh
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

10.  Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease.

Authors:  Minseok Seo; Weiliang Qiu; William Bailey; Gerard J Criner; Mark T Dransfield; Anne L Fuhlbrigge; John J Reilly; Mary Beth Scholand; Peter Castaldi; Robert Chase; Margaret Parker; Aabida Saferali; Jeong H Yun; James D Crapo; Michael H Cho; Terri H Beaty; Edwin K Silverman; Craig P Hersh
Journal:  J Mol Med (Berl)       Date:  2018-10-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.